All In Biotech

Drug Trial Radar · NCT00851942

Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test

Last checked: Nov 20, 2026Latest source record: Aug 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

165

Actual

Start

Sep 2008

Primary completion

Jul 28, 2012

Study completion Jan 31, 2013

Sponsor

Lead sponsor
Cardiff UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 26, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Objectives: To establish valid serum total cortisol and salivary cut-offs for use with the short Synacthen test in patients with normal CBG concentrations. To investigate, using current assays, the effect of assay differences on the serum total cortisol cut-off. To explore the performance of these cut-offs in groups of patients with suspected adrenal insufficiency and high and low serum CBG concentration. Methodology: An ACTH test (250 micrograms iv ACTH1-24) will be undertaken in healthy volunteers, women taking an oestrogen-containing oral contraceptive pill (OCP), patients with adrenal insufficiency and patients with low serum albumin. Serum cortisol in the samples collected from healthy volunteers will be measured using GC-MS, Advia Centaur (Siemens), Architect (Abbott), Modular Analytics E170 (Roche), Immulite 2000 (Siemens) and Access (Beckman) automated immunoassays. The estimated lower reference limit for the 30 min cortisol response to ACTH, defined as the 2.5th percentile of log-transformed concentrations, will be determined in this healthy population and used as a cut-off in the patient groups studied.

Conditions

  • Healthy
  • Adrenal Insufficiency
  • Hypopituitarism

Interventions

  • Synacthen (Tetracosactrin)Drug

    IV injection of 250 micrograms of Synacthen in 1ml

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary end-point of the study will be to establish method dependent cortisol cut offs for the normal response to Synacthen® using the 5th percentile.Time frame: Cortisol response at 30 minutes

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Facility, University Hospital of Wales

    Cardiff, South Glamorgan, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.